Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 -
Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific meeting -
- Conference call and live webcast at 8:30 a.m. ET today -
Conference Call and Webcast Details
| Title: | Humacyte Third Quarter 2024 Financial Results and Corporate Update |
| Date: | Friday, November 8, 2024 |
| Time: | 8:30 a.m. ET |
| Conference Call Details: | Toll-Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID #: 13749485 |
| Call meTM Feature (avoid waiting for operator): | Click Here |
| Webcast: | Webcast Link - Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.